This grant, offered by the Sickle Cell Disease Treatment Demonstration Program, aims to significantly improve access to quality, coordinated, and comprehensive care for individuals living with Sickle Cell Disease (SCD). Its primary purpose is to address current gaps in care by fostering a more knowledgeable healthcare workforce, enhancing the overall quality of medical services provided to SCD patients, and strengthening care coordination among various healthcare providers. The funding seeks to create a more integrated and effective support system, ensuring that individuals with SCD receive the comprehensive care necessary for managing their condition and improving their well-being.
Opportunity ID: 331673
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HRSA-21-032 |
| Funding Opportunity Title: | Sickle Cell Disease Treatment Demonstration Program |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=8d24c351-2384-4209-a572-19c0af5fbe62 |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.365 — Sickle Cell Treatment Demonstration Program |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 23, 2021 |
| Last Updated Date: | Feb 23, 2021 |
| Original Closing Date for Applications: | May 03, 2021 |
| Current Closing Date for Applications: | May 03, 2021 |
| Archive Date: | Jul 02, 2021 |
| Estimated Total Program Funding: | $5,000,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligible applicants include a Federally-qualified health center, a nonprofit hospital or clinic, or a university health center that provides primary health care, that has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals who have sickle cell disease; and demonstrates to the HRSA Administrator that either the federally-qualified health center, the nonprofit hospital or clinic, the university health center, the organization or entity described in clause (i) 42 USC § 300b-5, or experts as described in paragraph (2)(C) of 42 USC § 300b-5, has at least five (5) years of experience in working with individuals who have sickle cell disease. Federally-qualified health center is defined in section 1905(l)(2)(B) of the Social Security Act (42 U.S.C. 1396d(l)(2)(B)). |
Additional Information
| Agency Name: | Health Resources and Services Administration |
| Description: | This notice announces the opportunity to apply for funding under the Sickle Cell Disease Treatment Demonstration Program (TDP). The purpose of the TDP is to increase access for individuals with sickle cell disease (SCD) to quality, coordinated, comprehensive care by: 1) increasing the number of clinicians or health professionals knowledgeable about the care of SCD, 2) improving the quality of care provided to individuals with SCD, and 3) improving care coordination with other providers. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Department of Health and Human Services, Health Resources and Services Administration
akeehn@hrsa.gov Email:akeehn@hrsa.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 331673 Full Announcement-HRSA-21-032 -> HRSA-21-032.pdf
Packages
| Agency Contact Information: | Department of Health and Human Services, Health Resources and Services Administration akeehn@hrsa.gov Email: akeehn@hrsa.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.365 | HRSA-21-032 | Sickle Cell Disease Treatment Demonstration Program | PKG00265628 | Feb 23, 2021 | May 03, 2021 | View |
Package 1
Mandatory forms
331673 SF424_2_1-2.1.pdf
331673 AttachmentForm_1_2-1.2.pdf
331673 PerformanceSite_2_0-2.0.pdf
331673 ProjectNarrativeAttachments_1_2-1.2.pdf
331673 GG_LobbyingForm-1.1.pdf
331673 BudgetNarrativeAttachments_1_2-1.2.pdf
331673 SF424A-1.0.pdf
Optional forms
331673 SFLLL_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
